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Blood supply is crucial for rapid growth of a malignant tumor; medical imaging can play an important role in evaluating the
vascular characterstics of tumors. Magnetic resonance imaging (MRI) and micro-computed tomography (CT) are able to detect
tumors and measure blood volumes of microcirculation in tissue. In this study, we used MR imaging and micro-CT to assess the
microcirculation in a VX2 tumor model in rabbits. MRI characterization was performed using the intravascular contrast agent
Clariscan (NC100150-Injection); micro-CT with Microﬁl was used to directly depict blood vessels with diameters as low as 17um
in tissue. Relative blood volume fraction (rBVF) in the tumor rim and blood vessel density (rBVD) over the whole tumor was
calculatedusingthetwoimagingmethods.OurstudyindicatesthatrBVFisnegativelyrelatedtothevolumeofthetumormeasured
by ultrasound (R = 0.90). rBVF in the tissue of a VX2 tumor measured by MRI in vivo was qualitatively consistent with the rBVD
demonstrated by micro-CT in vitro (R = 0.97). The good correlation between the two methods indicates that MRI studies are
potentially valuable for assessing characteristics or tumor vascularity and for assessing response to therapy noninvasively.
1.Introduction
Medicalimagingisanimportantandusefultoolforassessing
the shape and structure of a tumor as it grows and for
monitoring the eﬀects of clinical treatments [1–3]. It has
been documented that increased vascularity in the neoplastic
tissueprovidesavaluableindicationoftumoraggressiveness;
this blood supply is crucial for the malignant tumor to grow
rapidly. Traditionally, the response to cancer treatment is
judged by the reduction in tumor volume. Recently, switch-
ing the target of cancer treatment from the exceptionally
heterogeneous tumor cell population to the considerably
more homogeneous tumor vasculature has emerged as a
revolutionary therapeutic approach. Development of a large
number of antivascular and antiangiogenic therapies has
created the need for techniques that noninvasively quantify
vascular volume and ﬂow changes in response to the therapy.
Assessment of structural and functional abnormalities of
a tumor’s blood vessels for prognostic reasons, therapy
monitoring, or prediction of therapy success is increasingly
gaining attention. The relative blood volume fraction in
selected regions (rBVF: a ratio of average signal contribution
in a region of the tumor due to intravascular agents relative
to that in whole blood, measured in vivo), can be determined
by 2D MRI using intravascular contrast agents [4, 5]. The
relative blood vessel density in the tumor (rBVD: percentage
of pixels within identiﬁable blood vessels relative to total
number of voxels in the tumor or tumor region) is best
measured by high-resolution micro-CT in vitro but may be
approximated by high-resolution 3D MRI in vivo.
A rabbit model with VX2 tumor has been studied widely
to assess tumor development and treatment response [6–
8]. In general, the tumor mass can be visualized as two
distinct regions: the highly vascular advancing rim where
tortuous blood vessels are abundant in the peripheral area
and the hypovascular central region where the number of




the tumor growth [9]. The rBVF and rBVD and the changes
of blood volume and vascular density with tumor growth
can be monitored using medical imaging. However, the
relationships between the functional rBVF measured by 2D2 Journal of Oncology
MRI in vivo, morphological rBVD measured by micro-CT in
vitro, and the size (volume) of the tumor have not yet been
reported.Therefore,thepurposeofthisstudywastoevaluate
the rBVF characteristics in the highly vascular advancing
rim of a rabbit VX2 tumor model by 2D MRI in vivo
and compared to rBVD measured by micro-CT in vitro to
validate a practical in vivo MRI method which could be used
to characterize the earlier functional response of a tumor
to clinical intervention and treatments. The blood vessel
density (rBVD) in the tumor demonstrated by micro-CT
and rBVD by 3-dimensional (3-D) MRI were also compared.
The relationships among rBVF and rBVD and the volume
of the VX2 tumor as it grows were evaluated as well. Micro-
CT can demonstrate the tumor’s 3D microangioarchitecture
and therefore can serve as a gold standard for perfused
blood volume; the minimal diameter of the blood vessels
detectable on micro-CT images was about 9 to 17μm[ 10,
11]. Histopathology was also performed to demonstrate
diﬀerencesin the structureof blood vessels in smalland large
tumors.
2.MaterialsandMethods
2.1. Animal Model. Nine New Zealand white rabbits (4 to
4.5kg) were used in this study. All animals were prepared
in accordance with the “Guide to the Care and use of
Experimental Animals (Canadian Council on Animal Care)”
under approved protocols. The rabbits were each injected
intramuscularlywithabout1×106 VX2tumorcellsinahind
leg. The tumor was monitored daily by B-mode ultrasound
starting at 7 days after injection of the tumor cells. When the
tumor reached at least 2cm3, an MRI study was scheduled.
Tumor volume was calculated at the time of the MRI study
from the maximum length, width, and height measured on
ultrasound images acquired the same day as length (cm)
∗ width (cm) ∗ height (cm) ∗ π/6, assuming a prolate
ellipsoid shape. Tumors were included with volumes ranging
from 2.4cm3 to 15.37cm3 based on studies at time points
rangingfrom10to20daysafterthetumorcellswereinjected.
MRI and micro-CT studies, for each tumor were conducted
within 24 hours. Rabbits were anaesthetized with Ketamine
(50mg/kg) and Xylazine (5mg/kg).
2.2. MRI. Studies were performed on a GE Signa 1.5TCV/i
equipped with 40mT/m gradients with a 150mT/m/s slew
rate using a 3-inch receive-only surface coil for signal
reception. The maximal center cross-section of the tumor
were imaged by 2D MRI with a T1-measurement acquisition.
2.2.1. 2D MRI. 2D Quantitative T1 measurements for rBVF
were made using a Look-Looker sequence with spiral
readouts (225ms acquisition spacing, TR = 3000ms, RBW =
125kHz, 20◦ ﬂip angle, 7mm slice thickness, FOV = 20cm,
4096 × 8 spiral readouts), 1.1mm resolution. The intravas-
cular contrast agent, Clariscan, (NC100150-Injection, GE
Healthcare) was used in this study. T1 measurements
were made both prior to and approximately 4 minutes
following an intravenous bolus injection of Clariscan
(0.05mL/kg = 0.15mgFe/kg), and then at 15-minute inter-
valsofdiﬀerenttimepoints thereafter.Dynamic T1-weighted
imaging for perfusion was performed immediately following
Clariscan injection and used for identifying the region of
interest (ROI) in the tumor rim (fast spoiled gradient echo
2DFT sequence, TR = 12ms, TE = 5ms, 30 ◦ ﬂip angle,
bandwidth=15.63kHz, Matrix = 256 ×128, FOV = 20cm).
A total of 10mL (5 × 2.0mL tubes) of arterial blood
was drawn both before and after the Clariscan injection at
diﬀerent time points and T1 decay times for each sample
was measured (TR = 3000ms, TE = 50ms, RBW = 125kHz,
10◦ ﬂip angle, 10mm slice thickness, FOV = 20cm, 6 NEX,
4096 × 4 spiral readouts) to calculate the T1 due to the
contrast agent in whole blood. The changes in longitudinal
relaxation rates R1 (1/T1) in blood after administration of
contrast medium is proportional to contrast agent con-
centration. Under the assumption that Clariscan remains
intravascular in the tumor, the blood volume fraction can be
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injectionofClariscan.T1t andT1b refertothemeasurements
from the tissue in vivo and the blood sample in vitro,
respectively. This equation assumes that we can model the
tumor as two pools, consisting of an intravascular and
extravascular compartments, and the distribution of protons
between the pools is equal (partition coeﬃcient = 1). In
addition, the exchange of protons between the pools is fast
enough that the system can be regarded as well mixed within
a time on the order of T1 [12]. Previous studies showed that
the condition of fast water exchange appears to be met when
T1 in blood is greater than 150ms [13, 14]. The postCA
measurement of Clariscan for rBVF measurement was taken
at the last time point (at 60 to 90min after injection) when
T1 of blood was >150ms to satisfy this condition.
2.2.2. 3D MRI. The 3D spoiled gradient echo acquisition
(3D SPGR, TR = 6ms, TE = 2ms, FOV = 20cm, 30◦
Flip angle, Bandwidth = 125kHz, slice thickness = 0.8mm,
320 × 320 pixels in-plane yielding approximately 0.6-mm
resolution) was also conducted before and 10 minutes after
Clariscan injection. Maximum Intensity Projection (MIP)
was obtained by subtraction of pre- from post-contrast
agent.
2.3. Micro-CT. When MRI in vivo studies was ﬁnished,
tumors were perfused via the femoral artery with saline
followed by microﬁl (Flow Tech inc., Carver, MA) for the
micro-CT study. The tumor was excised 90 minutes after
microﬁl perfusion to allow time for the microﬁl to harden;
the tumors were then stored in 10% formalin for 24 hours.
The specimen was then mounted in 10% gelatin and 3D
cone beam CT data sets were acquired over 2.5 hours with
905 views at 35μm-resolution using a micro-CT scanner
(MS-8, GE Medical Systems, London, Ontario). An X-ray
sourceofvoltage80kvpandabeamcurrent90μAw er eused.Journal of Oncology 3
A 3D data volume was reconstructed using the Feldkamp
a l g o r i t h mf o rc o n eb e a mC Tg e o m e t r y[ 11]. 3D surface
rendering of the vasculature of tumor was accomplished
using Display software (Montreal Neurological Institute,
McGill, Montreal, Canada).
2.4. Tissue Preparation and Histology. Since microﬁl used
for micro-CT makes it diﬃcult to interpret histology, we
examined samples from four additional VX2 tumors of
similarsizeshistologicallytoconﬁrmvascularcharacteristics.
T h e s ew e r eﬁ x e di n4 %P F Af o r4h o u r s ,w a s h e di nP B S3
times for 15 minutes, and cryoprotected in 15% sucrose in
PBS for 1 hour followed by 30% sucrose in PBS overnight
at 4◦C. Samples were then incubated in Tissue-Tek OCT
(Sakura) at 4◦C for 4 hours prior to embedding in OCT
over dry ice. The tissue blocks were cryosectioned at 7μm,
placed onto L-polylysine-coated slides (Fisher Scientiﬁc),
and dried for 1–4 hours at room temperature before storage
at −20◦C. Histology study was conducted by Immunohis-
tochemistry staning, the slides were incubated with alkaline
phosphatase conjugated monoclonal anti-α-Smooth muscle
actin (1:100; Sigma) for 1 hour at room temperature
followed by washing 4 times in PBS for 5min. This stain
was used to identify microvessels based on their smooth
muscle layer and was found to be adequate for this purpose
in the rabbit model. Then the sections were incubated
10min in alkaline phosphatase buﬀer (100mM Tris-HCl,
pH 9.5, 100mMNaCl, 10mMMgCl2) and then stained
with BM Purple AP substrate (100mM Tris-HCl, pH 9.5,
100mMNaCl, 50mMMgCl2, 0.01% sodium deoxycholate,
0.02% NP-40, 337mg/mL NBT (nitroblue tetrazolium salt;
Boehringer Ingelheim), and 175mg/mL BCIP (5-bromo-
4-chloro-3-indolyl phosphate, toluidinium salt; Boehringer
Mannheim). The staining reaction was allowed to proceed
for10minatroomtemperature.Theslideswerethenwashed
extensively in PBS and covered with cytoseal mounting
medium (Richard-Allan Scientiﬁc).
3.DataAnalysis
3.1. 2D MRI. ROIs were carefully placed around the abun-
dant microvascular rim of the tumor in both large and
small tumors for 2D measurements. The ROI in the rim
of tumor tissue avoids necrosis and bigger vessels in the
center of the tumor for correctly assessing the rBVF in
microcirculation. The ROIs were determined from serial
images taken immediately after injection of the contrast
agent Clariscan (published data) [15] in MRI as areas that
were ﬁlled with contrast agent at early phases and showed
clearer outlines for the tumor.
3.2. 3D MRI and Micro-CT. Measurements of vessel density,
rBVD, from 3D MRI and 3D micro-CT were determined by
rendering 3D isosurfaces in Amira (AmiraDev 4.1.1; TGS,
Berlin, Germany). Micro-CT images in vitro showed the
isolated tumor’s vessel clearly, however, Images of 3D MRI
in vivo demonstrated not only the tumors’ vessels but also
the blood vessels of whole leg, Therefore the MRI images and
micro-CT images were aligned using the big blood vessels
in the tumor, then the tumor was segmented by manually
drawing a volume using “Label/Voxel” to encompass the
whole tumor deﬁned by the vascular rim in the micro-CT
data. The blood vessel density over the tumor (rBVD) was
determined by counting voxels inside the surface-rendered
vessels and comparing that to the total number of voxels in
the tumor using the “TissueStatistics” package in Amira.
4.StatisticalAnalysis
The correlations between rBVF in the rim measured by
2D MRI and the volume of the tumor by ultrasound
were assessed with Pearson’s correlation coeﬃcient. The
relative blood volume fraction in 2D and the blood vessel
density in 3D MRI were compared. The blood vessel density
determined by 3D MRI and micro-CT were also compared.
Statistical signiﬁcance was set as P<0.05.
5. Results
5.1. rBVF Relative to Volume of the Tumor. Our results
indicated for the ﬁrst time that rBVF in the rim of the tumor
seems to decrease with increasing volume of VX2 tumors (as
measured by ultrasound) once the tumors were detectable
and measurable for rBVF (i.e., those larger than 2.4cm3
in this study). There was a signiﬁcant inverse relationship
between the rBVF and the volume of the tumor, R = 0.90,
P<0.001 (Figure 1). In our study, the rBVF in the tumor’s
rim varied from 3.05 to 16.55% with an average of 10.38 ±
5.36%, as measured by MRI; the volume of the tumors
ranged from 2.40 to 15.37cm3 with an average volume of
8.98 ± 4.82cm3, obtained by ultrasound.
5.2. rBVF in 2D Compared to rBVD in 3D MRI. The rBVF
in the rim measured by 2D MRI was signiﬁcantly correlated
with the rBVD across the tumor calculated from 3D MRI
(Figure 2, R = 0.95, P<0.001). The rBVF in the rim
measured in this study was derived in a slice at the maximum
cross-section of the tumor, and rBVD in 3D was calculated
from the whole volume of the tumor. The average rBVD in
3D was higher than the rBVF measured in 2D, likely due to
the greater coverage of tumor and inclusion of larger vessels
in the 3D acquisition.
5.3. Blood Vessel Density in Micro-CT Compared to 3D
MRI. The vessel density obtained by micro-CT yielded
results similar to corresponding measurements by 3D MRI
(Figure 3, R = 0.97, P<0.001). A representative large tumor
(>9.6cm3 in volume) had a lower density of blood vessels
(8.8% in micro-CT compared to the 4.0% derived from
MRI). The blood vessel density increased to 20% by micro-
CT and to 17% by 3D MRI in a small tumor around 2.8cm3
in volume. The smaller tumor demonstrated a thicker rim
with more blood vessels (Figure 4) while the larger tumor
showed a thin rim with fewer blood vessels (Figure 5)b y3 D
MRI and micro-CT.4 Journal of Oncology
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Figure 1: rBVF measured by MRI in a VX2 tumor is inversely
related with volume of tumor (cm3). R = 0.90, P<0.001.
rBVF in 2D and rBVD in 3D by MRI
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Figure 2: Relationship between rBVF measured by 2D MRI and
rBVD by 3D MRI. R = 0.95, P<0.001.
The imaging results were consistent with histopatho-
logical observations (Figures 6 and 7). In the histology
specimens, the small tumor showed more small vessels in
thesection,whilethelargetumorshowedfewerbloodvessels
with greater diameters as well as more necrosis.
6. Discussion
OurresultsindicatethattherBVFinthetumorrimmeasured
by noninvasive imaging methods was negatively related to
the volume of the tumor and that small tumors at earlier
stages of growth have a higher density of blood vessels than
in large tumors at the later stages of growth. Therefore,
the vasculature of the tumors changed at diﬀerent growth
stages [16, 17]. The higher rBVF and density of blood
vessels in small tumors may be related to their rapid growth
and the relative absence of necrosis. The large mature
tumor has a lower BVF and bigger vessels with more
arteriovenous shunts; these characteristics may be related to
3D rBVD (%) by m-CT and MRI
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Figure 3: Relationship of blood vessel density measured in 3D by
m-CT and MRI. R = 0.97, P<0.001.
thegreatermetastaticpotentialandthelowereﬃciencyofthe
treatments at later stages.
Micro-CT, using a microfocus X-ray source and high-
resolution detectors, could clearly observe the 3D microan-
gioarchitecture of the tumor in vitro. Interestingly, the
images were comparable with 3D MRI at much lower resolu-
tionusingintravascularcontrastagentsinvivo(Figures4and
5). The minimal diameter of the microvessel demonstrated
by micro-CT was 17μm .T h er e s o l u t i o ni n3 DM R Iin vivo
was 0.6-0.7mm in this study. This suggests that most of the
vessel area across the whole tumor is dominated by the larger
vessels.
Studies over the last decade have demonstrated that
althoughthemicrovesseldensity intumorsisheterogeneous,
the vasculature of the tumor may diﬀer substantially at
the diﬀerent stages of the growth [9]. Our results provided
imaging and histopathological evidence supporting these
conclusions.Attheearlierstagesofthetumor’sgrowth,more
blood vessels were shown in the peripheral rim of the tumor.
This could explain the rapid tumor growth and the greater
eﬃciency of treatments in earlier stages.
Clinical investigations have suggested that the incidence
of metastases in many cancer types is positively correlated
with the microvessel density in vascular hot spots of the
primary tumor [18–20]. Metastatic potential also could be
related to the increased prevalence of arteriovenous shunts.
These may facilitate extravasation and transportation of
larger cancer cell clusters. The structural and functional
abnormalities of the vessels in the bigger tumors also result
in regions that are poorly perfused and hence hypoxic. Some
studies have indicated that tumor hypoxia may also promote
tissue metastasis. Rofstad has stated in detail the theoretic
reasons of several mechanisms involved [21]. Hypoxia is also
a cause of resistance to certain medical and cytotoxic agents.
The poorly perfused, hypoxic tumor microenvironment may
also be resistant to radiation therapy, photodynamic therapy,
chemotherapy, and some forms of gene therapy.
Measurement of microvessel characteristics can aid in
assessing the stage of disease, the likelihood of metastasis,Journal of Oncology 5
5mm
Figure 4: Small tumor (2.8cm3)—left: 3D MRI, middle: micro-CT, right: whole tumor volume. A higher density of blood vessels is seen in
the peripheral rim. The large artery on the left side of the images is the feeding blood vessel for the tumor.
5mm
Figure 5: Large tumor (9.6cm3)—left: 3D MRI, middle: micro-CT, right: whole tumor volume. A lower density of blood vessels is seen in
the peripheral rim.
and prognosis under various treatment strategies for a wide
range of cancers [22–25]. Many studies have demonstrated
reductions in blood volume and blood vessel density in
tumors after antivascular and anti-angiogenic treatments
[26]. However, there are some reports indicating that
microvessel density in the tumor is not always an indicator
of anti-angiogenic therapeutic eﬃciency. These data demon-
strate that the absence of a drop in microvessel density does
not indicate that the agent is ineﬀective [27–29]. Because
anti-angiogenic agents act to inhibit neovessel formation,
measurements of preexisting microvessel density are not
suﬃcient to reveal the functional or angiogenic status of the
tumor neovasculature. Therefore, blood ﬂow in the tumor,
including the blood volume and the blood ﬂow velocity in
the microcirculation of tumor tissue, may be more sensitive
than the blood vessel density for evaluating the eﬃciency
of antiangiogenesis agents in the earlier stage of the drug
administration. As a histological index, the blood vessel
density could not be expected to change as quickly as the
blood volume and velocity in the micro-circulation of the
tumor in response to the treatments. Therefore MRI and
ultrasound, as noninvasive modalities for determining the
morphological and functional blood volume changes in the
tissue are useful and valuable tools [15] for evaluation of the
microvasculature during tumor growth, and also for moni-
toring as well as evaluating the functional characteristics of
vasculature in the tumor as an indicator of the eﬃciency
of anti-vascular and anti-angiogenic agents. One study
recently demonstrated that tumor blood ﬂow measured by
destruction-replenishment ultrasound was highly correlated
with the contrast enhancement estimated by CT images [30].
Our data indicated that relative blood volume and blood
vessel density in the microcirculation of tissue measured
by MRI is consistent with the vessel density determined
by micro-CT. The results indicated also that the MRI
measurements of rBVF and rBVD in the tumor reﬂect the
histological structure in the tissue.
7. Study Limitations
One limitation of the rBVF and rBVD evaluation is that the
magnetic resonance macromolecular agent, Clariscan, may6 Journal of Oncology
Figure 6: Histology section from a small tumor shows a higher
density of smaller vessels.
Figure 7: Histology section from a large tumor shows fewer and
relatively bigger vessels and necrosis.
slowly leak out of the blood vessels. All data was collected
within 1.5 hours of contrast injection in this study; this
should minimize the eﬀects of leaking. Another problem is
that we need blood samples for contrast agent concentration
calculation in the blood pool, which is time consuming. One
could measure the signal from a relatively large blood vessel
in vivo instead in future studies.
The relationship of the vascularity and volume of the
tumor may be diﬀerent when the volume of tumor is less
than 2.0cm3; however that was not included in this study.
Micro-CTand high-frequencyultrasoundmay be helpfulfor
evaluation of smaller tumors.
8. Conclusion
Relative blood volume in the microcirculation of tissue
as measured by MRI is valuable for determination of the
vascular,functional,andanatomiccharacteristicsofatumor,
as well as the changes with growth. The observations using
MRI and micro-CT have shown that rBVF and rBVD are
signiﬁcantly related to the characteristics and status of tumor
growth. This has immediate utility for preclinical research
studying the impact of novel therapeutics on tumor blood
supply. Speciﬁcally, the blood volume determination in the
tumor using the noninvasive MRI study may be useful
for monitoring and evaluating the eﬃciency of anticancer
drugs, especially anti-vascular and anti-angiogenic agents.
Such studies may also help elucidate optimal timing in
the administration of anti-vascular cancer therapies. This
noninvasive MRI technique could be extended to clinical
studies if and when an intravascular contrast agent similar
to Clariscan is approved for patient use.
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